Details of the Drug

General Information of Drug (ID: DMSL679)

Drug Name
Gatifloxacin
Synonyms
Bonoq; GTFX; Gaity; Gatiflo; Gatilox; Gatiquin; Gatispan; Tequin; Zymar; Zymaxid; Zymer; AM 1155; CG 5501;PD 135432; PD135432; AM-1155; BMS 206584-01; BMS-206584; CG-5501; Gatiflo (TN); Gatifloxacin & Gamma Interferon; Gatifloxacin (INN); Gatifloxacin (TN); Gatifloxacin [USAN:INN]; PD-135432; Tequin (TN); Tequin in dextrose 5% in plastic container; Zymar (TN); Zymer (TN); BMS-206584-01; Gatiflo,Tequin and Zymar, Gatifloxacin; AM-1155 (*Sesquihydrate*); (+-)-1-Cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-7-(3-methyl-1-piperazinyl)-4-oxo-3-quinolinecarboxylic acid; 1-Cyclopropyl-1,4-dihydro-6-fluoro-8-methoxy-7-(3-methyl-1-piperazinyl)-4-oxo-3-quinolinecarboxylic acid; 1-Cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-7-(3-methyl-1-piperazinyl)-4-oxo-3-quinolinecarboxylic acid; 1-cyclopropyl-6-fluoro-8-methoxy-7-(3-methylpiperazin-1-yl)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid; 1-cyclopropyl-6-fluoro-8-methoxy-7-(3-methylpiperazin-1-yl)-4-oxoquinoline-3-carboxylic acid
Indication
Disease Entry ICD 11 Status REF
Respiratory tract infection CA45 Approved [1]
Therapeutic Class
Antiinfective Agents
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 0 Molecular Weight (mw) 375.4
Topological Polar Surface Area (xlogp) -0.7
Rotatable Bond Count (rotbonds) 4
Hydrogen Bond Donor Count (hbonddonor) 2
Hydrogen Bond Acceptor Count (hbondacc) 8
ADMET Property
Bioavailability
The bioavailability of drug is 96% [2]
Clearance
The drug present in the plasma can be removed from the body at the rate of 2.8 mL/min/kg [3]
Half-life
The concentration or amount of drug in body reduced by one-half in 7 - 14 hours [3]
Unbound Fraction
The unbound fraction of drug in plasma is 0.8% [3]
Vd
Fluid volume that would be required to contain the amount of drug present in the body at the same concentration as in the plasma 1.7 L/kg [3]
Chemical Identifiers
Formula
C19H22FN3O4
IUPAC Name
1-cyclopropyl-6-fluoro-8-methoxy-7-(3-methylpiperazin-1-yl)-4-oxoquinoline-3-carboxylic acid
Canonical SMILES
CC1CN(CCN1)C2=C(C=C3C(=C2OC)N(C=C(C3=O)C(=O)O)C4CC4)F
InChI
InChI=1S/C19H22FN3O4/c1-10-8-22(6-5-21-10)16-14(20)7-12-15(18(16)27-2)23(11-3-4-11)9-13(17(12)24)19(25)26/h7,9-11,21H,3-6,8H2,1-2H3,(H,25,26)
InChIKey
XUBOMFCQGDBHNK-UHFFFAOYSA-N
Cross-matching ID
PubChem CID
5379
ChEBI ID
CHEBI:5280
CAS Number
112811-59-3
DrugBank ID
DB01044
TTD ID
D03CQE
VARIDT ID
DR01165

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Bacterial DNA gyrase (Bact gyrase) TTN6J5F GYRA_STAAU; GYRB_STAAU Modulator [4]
Staphylococcus Topoisomerase IV (Stap-coc parC) TTIXTO3 PARC_STAAS Modulator [4]

Drug Transporter (DTP)
DTP Name DTP ID UniProt ID MOA REF
Multidrug resistance-associated protein 2 (ABCC2) DTFI42L MRP2_HUMAN Substrate [5]
Organic anion transporting polypeptide 1A2 (SLCO1A2) DTE2B1D SO1A2_HUMAN Substrate [6]
P-glycoprotein 1 (ABCB1) DTUGYRD MDR1_HUMAN Substrate [7]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Disease Different from Gatifloxacin (Comorbidity)
DDI Drug Name DDI Drug ID Severity Mechanism Comorbidity REF
Ivosidenib DM8S6T7 Major Increased risk of prolong QT interval by the combination of Gatifloxacin and Ivosidenib. Acute myeloid leukaemia [2A60] [41]
Midostaurin DMI6E0R Major Increased risk of prolong QT interval by the combination of Gatifloxacin and Midostaurin. Acute myeloid leukaemia [2A60] [41]
Idarubicin DMM0XGL Major Increased risk of prolong QT interval by the combination of Gatifloxacin and Idarubicin. Acute myeloid leukaemia [2A60] [41]
Arn-509 DMT81LZ Major Increased risk of prolong QT interval by the combination of Gatifloxacin and Arn-509. Acute myeloid leukaemia [2A60] [41]
Gilteritinib DMWQ4MZ Major Increased risk of prolong QT interval by the combination of Gatifloxacin and Gilteritinib. Acute myeloid leukaemia [2A60] [41]
Oliceridine DM6MDCF Major Increased risk of prolong QT interval by the combination of Gatifloxacin and Oliceridine. Acute pain [MG31] [41]
Ivabradine DM0L594 Major Increased risk of ventricular arrhythmias by the combination of Gatifloxacin and Ivabradine. Angina pectoris [BA40] [42]
Bepridil DM0RKS4 Major Increased risk of prolong QT interval by the combination of Gatifloxacin and Bepridil. Angina pectoris [BA40] [43]
Dronedarone DMA8FS5 Major Increased risk of prolong QT interval by the combination of Gatifloxacin and Dronedarone. Angina pectoris [BA40] [44]
Bedaquiline DM3906J Major Increased risk of prolong QT interval by the combination of Gatifloxacin and Bedaquiline. Antimicrobial drug resistance [MG50-MG52] [41]
Cilostazol DMZMSCT Major Increased risk of prolong QT interval by the combination of Gatifloxacin and Cilostazol. Arterial occlusive disease [BD40] [41]
Posaconazole DMUL5EW Major Increased risk of prolong QT interval by the combination of Gatifloxacin and Posaconazole. Aspergillosis [1F20] [41]
Levalbuterol DM5YBO1 Moderate Increased risk of ventricular arrhythmias by the combination of Gatifloxacin and Levalbuterol. Asthma [CA23] [45]
Pirbuterol DMI5678 Moderate Increased risk of prolong QT interval by the combination of Gatifloxacin and Pirbuterol. Asthma [CA23] [45]
Lisdexamfetamine DM6W8V5 Major Increased risk of prolong QT interval by the combination of Gatifloxacin and Lisdexamfetamine. Attention deficit hyperactivity disorder [6A05] [41]
Desipramine DMT2FDC Major Increased risk of prolong QT interval by the combination of Gatifloxacin and Desipramine. Attention deficit hyperactivity disorder [6A05] [41]
Clarithromycin DM4M1SG Major Increased risk of prolong QT interval by the combination of Gatifloxacin and Clarithromycin. Bacterial infection [1A00-1C4Z] [41]
Retigabine DMGNYIH Major Increased risk of prolong QT interval by the combination of Gatifloxacin and Retigabine. Behcet disease [4A62] [41]
Lomustine DMMWSUL Minor Decreased absorption of Gatifloxacin due to intestinal mucosa variation caused by Lomustine. Brain cancer [2A00] [46]
Eribulin DM1DX4Q Major Increased risk of prolong QT interval by the combination of Gatifloxacin and Eribulin. Breast cancer [2C60-2C6Y] [41]
Lapatinib DM3BH1Y Major Increased risk of prolong QT interval by the combination of Gatifloxacin and Lapatinib. Breast cancer [2C60-2C6Y] [41]
Thiotepa DMIZKOP Minor Decreased absorption of Gatifloxacin due to intestinal mucosa variation caused by Thiotepa. Breast cancer [2C60-2C6Y] [46]
Bosutinib DMTI8YE Major Increased risk of prolong QT interval by the combination of Gatifloxacin and Bosutinib. Breast cancer [2C60-2C6Y] [41]
PF-04449913 DMSB068 Major Increased risk of prolong QT interval by the combination of Gatifloxacin and PF-04449913. Chronic myelomonocytic leukaemia [2A40] [41]
Olodaterol DM62B78 Moderate Increased risk of prolong QT interval by the combination of Gatifloxacin and Olodaterol. Chronic obstructive pulmonary disease [CA22] [47]
Vilanterol DMF5EK1 Moderate Increased risk of ventricular arrhythmias by the combination of Gatifloxacin and Vilanterol. Chronic obstructive pulmonary disease [CA22] [45]
Indacaterol DMQJHR7 Moderate Increased risk of prolong QT interval by the combination of Gatifloxacin and Indacaterol. Chronic obstructive pulmonary disease [CA22] [47]
Arformoterol DMYM974 Moderate Increased risk of prolong QT interval by the combination of Gatifloxacin and Arformoterol. Chronic obstructive pulmonary disease [CA22] [47]
Capecitabine DMTS85L Minor Decreased absorption of Gatifloxacin due to intestinal mucosa variation caused by Capecitabine. Colorectal cancer [2B91] [46]
Isoproterenol DMK7MEY Major Increased risk of ventricular arrhythmias by the combination of Gatifloxacin and Isoproterenol. Conduction disorder [BC63] [47]
Mestranol DMG3F94 Moderate Decreased absorption of Gatifloxacin due to formation of complexes caused by Mestranol. Contraceptive management [QA21] [48]
Halothane DM80OZ5 Major Increased risk of prolong QT interval by the combination of Gatifloxacin and Halothane. Corneal disease [9A76-9A78] [41]
Sevoflurane DMC9O43 Major Increased risk of prolong QT interval by the combination of Gatifloxacin and Sevoflurane. Corneal disease [9A76-9A78] [41]
Probucol DMVZQ2M Major Increased risk of prolong QT interval by the combination of Gatifloxacin and Probucol. Coronary atherosclerosis [BA80] [41]
Pasireotide DMHM7JS Major Increased risk of prolong QT interval by the combination of Gatifloxacin and Pasireotide. Cushing syndrome [5A70] [41]
Osilodrostat DMIJC9X Major Increased risk of prolong QT interval by the combination of Gatifloxacin and Osilodrostat. Cushing syndrome [5A70] [41]
Sertraline DM0FB1J Major Increased risk of prolong QT interval by the combination of Gatifloxacin and Sertraline. Depression [6A70-6A7Z] [41]
Escitalopram DMFK9HG Major Increased risk of prolong QT interval by the combination of Gatifloxacin and Escitalopram. Depression [6A70-6A7Z] [44]
Clomipramine DMINRKW Major Increased risk of prolong QT interval by the combination of Gatifloxacin and Clomipramine. Depression [6A70-6A7Z] [41]
Doxepin DMPI98T Major Increased risk of prolong QT interval by the combination of Gatifloxacin and Doxepin. Depression [6A70-6A7Z] [41]
Tetrabenazine DMYWQ0O Major Increased risk of prolong QT interval by the combination of Gatifloxacin and Tetrabenazine. Dissociative neurological symptom disorder [6B60] [41]
Deutetrabenazine DMUPFLI Major Increased risk of prolong QT interval by the combination of Gatifloxacin and Deutetrabenazine. Dystonic disorder [8A02] [41]
Ingrezza DMVPLNC Major Increased risk of prolong QT interval by the combination of Gatifloxacin and Ingrezza. Dystonic disorder [8A02] [41]
Solifenacin DMG592Q Major Increased risk of prolong QT interval by the combination of Gatifloxacin and Solifenacin. Functional bladder disorder [GC50] [41]
Sunitinib DMCBJSR Major Increased risk of prolong QT interval by the combination of Gatifloxacin and Sunitinib. Gastrointestinal stromal tumour [2B5B] [41]
Procarbazine DMIK367 Minor Decreased absorption of Gatifloxacin due to intestinal mucosa variation caused by Procarbazine. Hodgkin lymphoma [2B30] [46]
Fostemsavir DM50ILT Major Increased risk of prolong QT interval by the combination of Gatifloxacin and Fostemsavir. Human immunodeficiency virus disease [1C60-1C62] [41]
Saquinavir DMG814N Major Increased risk of prolong QT interval by the combination of Gatifloxacin and Saquinavir. Human immunodeficiency virus disease [1C60-1C62] [49]
Lopinavir DMITQS0 Major Increased risk of prolong QT interval by the combination of Gatifloxacin and Lopinavir. Human immunodeficiency virus disease [1C60-1C62] [41]
Rilpivirine DMJ0QOW Major Increased risk of prolong QT interval by the combination of Gatifloxacin and Rilpivirine. Human immunodeficiency virus disease [1C60-1C62] [41]
Bempedoic acid DM1CI9R Major Increased risk of tendinitis/tendon rupture by the combination of Gatifloxacin and Bempedoic acid. Hyper-lipoproteinaemia [5C80] [50]
Melatonin DMKWFBT Minor Decreased metabolism of Gatifloxacin caused by Melatonin mediated inhibition of CYP450 enzyme. Insomnia [7A00-7A0Z] [51]
Iron DMAP8MV Moderate Decreased absorption of Gatifloxacin due to formation of complexes caused by Iron. Iron deficiency anaemia [3A00] [52]
Polyethylene glycol DM4I1JP Moderate Increased risk of lowers seizure threshold by the combination of Gatifloxacin and Polyethylene glycol. Irritable bowel syndrome [DD91] [44]
Phenolphthalein DM5SICT Moderate Increased risk of ventricular arrhythmias by the combination of Gatifloxacin and Phenolphthalein. Irritable bowel syndrome [DD91] [51]
Crizotinib DM4F29C Major Increased risk of prolong QT interval by the combination of Gatifloxacin and Crizotinib. Lung cancer [2C25] [53]
Ceritinib DMB920Z Major Increased risk of prolong QT interval by the combination of Gatifloxacin and Ceritinib. Lung cancer [2C25] [44]
Lurbinectedin DMEFRTZ Minor Decreased absorption of Gatifloxacin due to intestinal mucosa variation caused by Lurbinectedin. Lung cancer [2C25] [46]
Osimertinib DMRJLAT Major Increased risk of prolong QT interval by the combination of Gatifloxacin and Osimertinib. Lung cancer [2C25] [41]
Selpercatinib DMZR15V Major Increased risk of prolong QT interval by the combination of Gatifloxacin and Selpercatinib. Lung cancer [2C25] [41]
Halofantrine DMOMK1V Major Increased risk of prolong QT interval by the combination of Gatifloxacin and Halofantrine. Malaria [1F40-1F45] [51]
Hydroxychloroquine DMSIVND Major Increased risk of prolong QT interval by the combination of Gatifloxacin and Hydroxychloroquine. Malaria [1F40-1F45] [41]
Primaquine DMWQ16I Major Increased risk of prolong QT interval by the combination of Gatifloxacin and Primaquine. Malaria [1F40-1F45] [41]
Inotuzumab ozogamicin DMAC130 Major Increased risk of prolong QT interval by the combination of Gatifloxacin and Inotuzumab ozogamicin. Malignant haematopoietic neoplasm [2B33] [41]
Fludarabine DMVRLT7 Minor Decreased absorption of Gatifloxacin due to intestinal mucosa variation caused by Fludarabine. Malignant haematopoietic neoplasm [2B33] [46]
Arsenic trioxide DM61TA4 Major Increased risk of prolong QT interval by the combination of Gatifloxacin and Arsenic trioxide. Mature B-cell lymphoma [2A85] [54]
Vemurafenib DM62UG5 Major Increased risk of prolong QT interval by the combination of Gatifloxacin and Vemurafenib. Melanoma [2C30] [44]
Lanthanum carbonate DMMJQSH Moderate Decreased absorption of Gatifloxacin due to formation of complexes caused by Lanthanum carbonate. Mineral absorption/transport disorder [5C64] [44]
Panobinostat DM58WKG Major Increased risk of prolong QT interval by the combination of Gatifloxacin and Panobinostat. Multiple myeloma [2A83] [55]
Melphalan flufenamide DMWF5R4 Minor Decreased absorption of Gatifloxacin due to intestinal mucosa variation caused by Melphalan flufenamide. Multiple myeloma [2A83] [46]
Siponimod DM2R86O Major Increased risk of ventricular arrhythmias by the combination of Gatifloxacin and Siponimod. Multiple sclerosis [8A40] [51]
Fingolimod DM5JVAN Major Increased risk of ventricular arrhythmias by the combination of Gatifloxacin and Fingolimod. Multiple sclerosis [8A40] [44]
Ozanimod DMT6AM2 Major Increased risk of prolong QT interval by the combination of Gatifloxacin and Ozanimod. Multiple sclerosis [8A40] [41]
Deflazacort DMV0RNS Major Increased risk of tendinitis/tendon rupture by the combination of Gatifloxacin and Deflazacort. Muscular dystrophy [8C70] [56]
Nilotinib DM7HXWT Major Increased risk of prolong QT interval by the combination of Gatifloxacin and Nilotinib. Myeloproliferative neoplasm [2A20] [44]
Dasatinib DMJV2EK Major Increased risk of prolong QT interval by the combination of Gatifloxacin and Dasatinib. Myeloproliferative neoplasm [2A20] [41]
Promethazine DM6I5GR Major Increased risk of prolong QT interval by the combination of Gatifloxacin and Promethazine. Nausea/vomiting [MD90] [41]
Bupropion DM5PCS7 Major Increased risk of lowers seizure threshold by the combination of Gatifloxacin and Bupropion. Nicotine use disorder [6C4A] [57]
Entrectinib DMMPTLH Major Increased risk of prolong QT interval by the combination of Gatifloxacin and Entrectinib. Non-small cell lung cancer [2C25] [41]
Levomethadyl Acetate DM06HG5 Major Increased risk of prolong QT interval by the combination of Gatifloxacin and Levomethadyl Acetate. Opioid use disorder [6C43] [42]
Lofexidine DM1WXA6 Major Increased risk of prolong QT interval by the combination of Gatifloxacin and Lofexidine. Opioid use disorder [6C43] [41]
Rucaparib DM9PVX8 Major Increased risk of prolong QT interval by the combination of Gatifloxacin and Rucaparib. Ovarian cancer [2C73] [41]
Ibuprofen DM8VCBE Moderate Additive CNS depression effects by the combination of Gatifloxacin and Ibuprofen. Pain [MG30-MG3Z] [58]
Triclabendazole DMPWGBR Major Increased risk of prolong QT interval by the combination of Gatifloxacin and Triclabendazole. Parasitic worm infestation [1F90] [41]
Pimavanserin DMR7IVC Major Increased risk of prolong QT interval by the combination of Gatifloxacin and Pimavanserin. Parkinsonism [8A00] [41]
Macimorelin DMQYJIR Major Increased risk of prolong QT interval by the combination of Gatifloxacin and Macimorelin. Pituitary gland disorder [5A60-5A61] [59]
Lefamulin DME6G97 Major Increased risk of prolong QT interval by the combination of Gatifloxacin and Lefamulin. Pneumonia [CA40] [59]
Choline salicylate DM8P137 Moderate Additive CNS stimulant effects by the combination of Gatifloxacin and Choline salicylate. Postoperative inflammation [1A00-CA43] [60]
Degarelix DM3O8QY Major Increased risk of prolong QT interval by the combination of Gatifloxacin and Degarelix. Prostate cancer [2C82] [41]
ABIRATERONE DM8V75C Major Increased risk of prolong QT interval by the combination of Gatifloxacin and ABIRATERONE. Prostate cancer [2C82] [41]
Enzalutamide DMGL19D Major Increased risk of prolong QT interval by the combination of Gatifloxacin and Enzalutamide. Prostate cancer [2C82] [41]
Relugolix DMK7IWL Major Increased risk of prolong QT interval by the combination of Gatifloxacin and Relugolix. Prostate cancer [2C82] [41]
Bicalutamide DMZMSPF Major Increased risk of prolong QT interval by the combination of Gatifloxacin and Bicalutamide. Prostate cancer [2C82] [41]
Levomepromazine DMIKFEL Major Increased risk of prolong QT interval by the combination of Gatifloxacin and Levomepromazine. Psychotic disorder [6A20-6A25] [41]
Salsalate DM13P4C Moderate Additive CNS stimulant effects by the combination of Gatifloxacin and Salsalate. Rheumatoid arthritis [FA20] [58]
Dexamethasone DMMWZET Major Increased risk of tendinitis/tendon rupture by the combination of Gatifloxacin and Dexamethasone. Rheumatoid arthritis [FA20] [56]
Quetiapine DM1N62C Major Increased risk of prolong QT interval by the combination of Gatifloxacin and Quetiapine. Schizophrenia [6A20] [41]
Aripiprazole DM3NUMH Moderate Increased risk of prolong QT interval by the combination of Gatifloxacin and Aripiprazole. Schizophrenia [6A20] [51]
Iloperidone DM6AUFY Major Increased risk of prolong QT interval by the combination of Gatifloxacin and Iloperidone. Schizophrenia [6A20] [44]
Paliperidone DM7NPJS Major Increased risk of prolong QT interval by the combination of Gatifloxacin and Paliperidone. Schizophrenia [6A20] [41]
Amisulpride DMSJVAM Major Increased risk of prolong QT interval by the combination of Gatifloxacin and Amisulpride. Schizophrenia [6A20] [41]
Asenapine DMSQZE2 Major Increased risk of prolong QT interval by the combination of Gatifloxacin and Asenapine. Schizophrenia [6A20] [41]
Pimozide DMW83TP Major Increased risk of prolong QT interval by the combination of Gatifloxacin and Pimozide. Schizophrenia [6A20] [42]
Ifosfamide DMCT3I8 Minor Decreased absorption of Gatifloxacin due to intestinal mucosa variation caused by Ifosfamide. Solid tumour/cancer [2A00-2F9Z] [46]
Docetaxel DMDI269 Minor Decreased absorption of Gatifloxacin due to intestinal mucosa variation caused by Docetaxel. Solid tumour/cancer [2A00-2F9Z] [46]
Mitoxantrone DMM39BF Minor Decreased absorption of Gatifloxacin due to intestinal mucosa variation caused by Mitoxantrone. Solid tumour/cancer [2A00-2F9Z] [46]
LEE011 DMMX75K Major Increased risk of prolong QT interval by the combination of Gatifloxacin and LEE011. Solid tumour/cancer [2A00-2F9Z] [41]
Vandetanib DMRICNP Major Increased risk of prolong QT interval by the combination of Gatifloxacin and Vandetanib. Solid tumour/cancer [2A00-2F9Z] [44]
Triptorelin DMTK4LS Major Increased risk of prolong QT interval by the combination of Gatifloxacin and Triptorelin. Solid tumour/cancer [2A00-2F9Z] [41]
Taxol DMUOT9V Minor Decreased absorption of Gatifloxacin due to intestinal mucosa variation caused by Taxol. Solid tumour/cancer [2A00-2F9Z] [46]
Pitolisant DM8RFNJ Major Increased risk of prolong QT interval by the combination of Gatifloxacin and Pitolisant. Somnolence [MG42] [41]
Telavancin DM58VQX Major Increased risk of prolong QT interval by the combination of Gatifloxacin and Telavancin. Staphylococcal/streptococcal disease [1B5Y] [41]
Plicamycin DM7C8YV Minor Decreased absorption of Gatifloxacin due to intestinal mucosa variation caused by Plicamycin. Testicular cancer [2C80] [46]
Lenvatinib DMB1IU4 Major Increased risk of prolong QT interval by the combination of Gatifloxacin and Lenvatinib. Thyroid cancer [2D10] [41]
Cabozantinib DMIYDT4 Major Increased risk of prolong QT interval by the combination of Gatifloxacin and Cabozantinib. Thyroid cancer [2D10] [41]
Papaverine DMCA9QP Major Increased risk of prolong QT interval by the combination of Gatifloxacin and Papaverine. Tonus and reflex abnormality [MB47] [61]
Trimeprazine DMEMV9D Major Increased risk of prolong QT interval by the combination of Gatifloxacin and Trimeprazine. Vasomotor/allergic rhinitis [CA08] [41]
Propafenone DMPIBJK Major Increased risk of prolong QT interval by the combination of Gatifloxacin and Propafenone. Ventricular tachyarrhythmia [BC71] [41]
Flecainide DMSQDLE Major Increased risk of prolong QT interval by the combination of Gatifloxacin and Flecainide. Ventricular tachyarrhythmia [BC71] [41]
Amiodarone DMUTEX3 Major Increased risk of prolong QT interval by the combination of Gatifloxacin and Amiodarone. Ventricular tachyarrhythmia [BC71] [41]
⏷ Show the Full List of 120 DDI Information of This Drug

References

1 Novel agents in the management of Mycobacterium tuberculosis disease. Curr Med Chem. 2007;14(18):2000-8.
2 FDA approval: ado-trastuzumab emtansine for the treatment of patients with HER2-positive metastatic breast cancer. Clin Cancer Res. 2014 Sep 1;20(17):4436-41.
3 Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
4 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
5 Uptake and intracellular release kinetics of liposome formulations in glioma cells. Int J Pharm. 2010 Aug 16;395(1-2):251-9.
6 Identification of influx transporter for the quinolone antibacterial agent levofloxacin. Mol Pharm. 2007 Jan-Feb;4(1):85-94.
7 Interaction of gatifloxacin with efflux transporters: a possible mechanism for drug resistance. Int J Pharm. 2010 Aug 16;395(1-2):114-21.
8 Involvement of the drug transporters p glycoprotein and multidrug resistance-associated protein Mrp2 in telithromycin transport. Antimicrob Agents Chemother. 2006 Jan;50(1):80-7.
9 Dose-dependent disposition of methotrexate in Abcc2 and Abcc3 gene knockout murine models. Drug Metab Dispos. 2011 Nov;39(11):2155-61.
10 Mammalian multidrug-resistance proteins (MRPs). Essays Biochem. 2011 Sep 7;50(1):179-207.
11 Enhancing chemosensitivity in oral squamous cell carcinoma by lentivirus vector-mediated RNA interference targeting EGFR and MRP2. Oncol Lett. 2016 Sep;12(3):2107-2114.
12 Multidrug resistance associated protein 2 mediates transport of prostaglandin E2. Liver Int. 2006 Apr;26(3):362-8.
13 Lentivirus-mediated RNAi silencing targeting ABCC2 increasing the sensitivity of a human nasopharyngeal carcinoma cell line against cisplatin. J Transl Med. 2008 Oct 4;6:55.
14 Effect of acetaminophen on expression and activity of rat liver multidrug resistance-associated protein 2 and P-glycoprotein. Biochem Pharmacol. 2004 Aug 15;68(4):791-8.
15 Small intestinal efflux mediated by MRP2 and BCRP shifts sulfasalazine intestinal permeability from high to low, enabling its colonic targeting. Am J Physiol Gastrointest Liver Physiol. 2009 Aug;297(2):G371-7.
16 Delineating the contribution of secretory transporters in the efflux of etoposide using Madin-Darby canine kidney (MDCK) cells overexpressing P-glycoprotein (Pgp), multidrug resistance-associated protein (MRP1), and canalicular multispecific organic anion transporter (cMOAT). Drug Metab Dispos. 2002 Apr;30(4):457-63.
17 Multidrug Resistance-Associated Protein 2 (MRP2) Mediated Transport of Oxaliplatin-Derived Platinum in Membrane Vesicles. PLoS One. 2015 Jul 1;10(7):e0130727.
18 Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007.
19 MDR1 (ABCB1) G1199A (Ser400Asn) polymorphism alters transepithelial permeability and sensitivity to anticancer agents. Cancer Chemother Pharmacol. 2009 Jun;64(1):183-8.
20 Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64.
21 Folate transporter expression decreases in the human placenta throughout pregnancy and in pre-eclampsia. Pregnancy Hypertens. 2012 Apr;2(2):123-31.
22 Comparative studies on in vitro methods for evaluating in vivo function of MDR1 P-glycoprotein. Pharm Res. 2001 Dec;18(12):1660-8.
23 Antiestrogens and steroid hormones: substrates of the human P-glycoprotein. Biochem Pharmacol. 1994 Jul 19;48(2):287-92.
24 Association of genetic polymorphisms in the influx transporter SLCO1B3 and the efflux transporter ABCB1 with imatinib pharmacokinetics in patients with chronic myeloid leukemia. Ther Drug Monit. 2011 Apr;33(2):244-50.
25 Interaction of methotrexate with organic-anion transporting polypeptide 1A2 and its genetic variants. J Pharmacol Exp Ther. 2006 Aug;318(2):521-9.
26 Localization of organic anion transporting polypeptide 4 (Oatp4) in rat liver and comparison of its substrate specificity with Oatp1, Oatp2 and Oatp3. Pflugers Arch. 2001 Nov;443(2):188-95.
27 Environmental and genetic factors affecting transport of imatinib by OATP1A2. Clin Pharmacol Ther. 2011 Jun;89(6):816-20.
28 Influence of the flavonoids apigenin, kaempferol, and quercetin on the function of organic anion transporting polypeptides 1A2 and 2B1. Biochem Pharmacol. 2010 Dec 1;80(11):1746-53.
29 Transporter-mediated influx and efflux mechanisms of pitavastatin, a new inhibitor of HMG-CoA reductase. J Pharm Pharmacol. 2005 Oct;57(10):1305-11.
30 Drug and bile acid transporters in rosuvastatin hepatic uptake: function, expression, and pharmacogenetics. Gastroenterology. 2006 May;130(6):1793-806.
31 Human organic anion-transporting polypeptide OATP-A (SLC21A3) acts in concert with P-glycoprotein and multidrug resistance protein 2 in the vectorial transport of Saquinavir in Hep G2 cells. Mol Pharm. 2004 Jan 12;1(1):49-56.
32 Uptake of enalapril and expression of organic anion transporting polypeptide 1 in zonal, isolated rat hepatocytes. Drug Metab Dispos. 2000 Jul;28(7):801-6.
33 Molecular and functional characterization of an organic anion transporting polypeptide cloned from human liver. Gastroenterology. 1995 Oct;109(4):1274-82.
34 Identification of thyroid hormone transporters in humans: different molecules are involved in a tissue-specific manner. Endocrinology. 2001 May;142(5):2005-12.
35 Grepafloxacin, a dimethyl derivative of ciprofloxacin, acts preferentially through gyrase in Streptococcus pneumoniae: role of the C-5 group in tar... Antimicrob Agents Chemother. 2002 Feb;46(2):582-5.
36 In vitro and in vivo antibacterial activity of T-3912, a novel non-fluorinated topical quinolone. J Antimicrob Chemother. 2002 Mar;49(3):455-65.
37 Hughes B: 2009 FDA drug approvals. Nat Rev Drug Discov. 2010 Feb;9(2):89-92.
38 2014 FDA drug approvals. Nat Rev Drug Discov. 2015 Feb;14(2):77-81.
39 2017 FDA drug approvals.Nat Rev Drug Discov. 2018 Feb;17(2):81-85.
40 DNA gyrase and topoisomerase IV are dual targets of zabofloxacin in Streptococcus pneumoniae.Int J Antimicrob Agents.2010 Jul;36(1):97-8.
41 Ansari SR, Chopra N "Gatifloxacin and Prolonged QT Interval." Am J Med Sci 327 (2004): 55-6. [PMID: 14722399]
42 Cerner Multum, Inc. "UK Summary of Product Characteristics.".
43 Owens RC "Risk assessment for antimicrobial agent-induced QTc interval prolongation and torsades de pointes." Pharmacotherapy 21 (2001): 301-19. [PMID: 11253855]
44 Canadian Pharmacists Association.
45 Product Information. Arcapta Neohaler (indacaterol). Novartis Pharmaceuticals, East Hanover, NJ.
46 Johnson EJ, MacGowan AP, Potter MN, et al "Reduced absorption of oral ciprofloxacin after chemotherapy for haematological malignancy." J Antimicrob Chemother 25 (1990): 837-42. [PMID: 2373666]
47 Bengtsson B, Fagerstrom PO "Extrapulmonary effects of terbutaline during prolonged administration." Clin Pharmacol Ther 31 (1982): 726-32. [PMID: 7042176]
48 Friedman CI, Huneke AL, Kim MH, Powell J "The effect of ampicillin on oral contraceptive effectiveness." Obstet Gynecol 55 (1980): 33-7. [PMID: 7188714]
49 Anson BD, Weaver JG, Ackerman MJ, et al. "Blockade of HERG channels by HIV protease inhibitors." Lancet 365 (2005): 682-686. [PMID: 15721475]
50 Product Information. Nexletol (bempedoic acid). Esperion Therapeutics, Ann Arbor, MI.
51 Cerner Multum, Inc. "Australian Product Information.".
52 Nix DE, Wilton JH, Ronald B, Distlerath L, Williams VC, Norman A "Inhibition of norfloxacin absorption by antacids." Antimicrob Agents Chemother 34 (1990): 432-5. [PMID: 2334155]
53 Product Information. Xalkori (crizotinib). Pfizer U.S. Pharmaceuticals Group, New York, NY.
54 Ohnishi K, Yoshida H, Shigeno K, et al. "Prolongation of the QT interval and ventricular tachycardia in patients treated with arsenic trioxide for acute promyelocytic leukemia." Ann Intern Med 133 (2000): 881-5. [PMID: 11103058]
55 Product Information. Farydak (panobinostat). Novartis Pharmaceuticals, East Hanover, NJ.
56 FDA. U.S. Food and Drug Administration "Information for Healthcare Professionals. Fluoroquinolone Antimicrobial Drugs. FDA Alert [7/8/2008].".
57 Product Information. Wellbutrin XL (buPROPion). GlaxoSmithKline, Philadelphia, PA.
58 Product Information. Factive (gemifloxacin). GeneSoft Inc, San Francisco, CA.
59 Product Information. Fycompa (perampanel). Eisai Inc, Teaneck, NJ.
60 Davey PG "Overview of drug interactions with the quinolones." J Antimicrob Chemother 22(suppl c) (1988): 97-107. [PMID: 3053579]
61 Goto M, Sato M, Kitzazawa H, et.al "Papaverine-induced QT interval prolongation and ventricular fibrillation in a patient with a history of drug-induced QT prolongation." Intern Med 53 (2014): 1629-31. [PMID: 25088875]